secwatch.observer — SEC 8-K summary
======================================

Issuer:     AI Financial Corp (AIFC)
CIK:        0000862861
Form:       8-K
Filed at:   2023-01-04T23:59:59+00:00
Accession:  0000950170-23-000135
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 3.02, 5.03
LLM model:  deepseek-v4-flash:cloud@v2

JanOne acquires Soin Therapeutics in up to $30M stock deal for CRPS naltrexone drug
--------------------------------------------------------------------------------

- All-stock acquisition valued at initial $13M, with potential earn-out up to $30M based on product revenues.
- Product is low-dose naltrexone for Complex Regional Pain Syndrome (CRPS); FDA granted Orphan Drug Designation.
- Dr. Amol Soin, founder, becomes Chief Medical Officer for at least six months post-closing.
- Issued 100,000 shares of Series S Convertible Preferred Stock (stated value $300/share) with conversion restrictions.
- Orphan designation provides tax credits, fee exemptions, and potential 7-year market exclusivity upon approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/862861/000095017023000135/0000950170-23-000135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/862861/000095017023000135/jan-20221228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer